Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
You may also be interested in...
First Blood-Based Lung Cancer EGFR Test Gets FDA Green Light
Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.